JohnnyRoger

Elan, Biogen Idec Won't Gain Much from Tysabri Approval

Brett,

I am going to try to be charitable considering your knowledge base and obvious limited knowledge of biopharaceutial companies and market research.

You must spend more time researching your subject! J&J owns Remicade, not Schering-Plough.

The Tysabri franchise HAS suffered and it is as a result of misinformed writers who simply quote other misinformed folks and spread fear to patients and potential investors. This type of shoot from the hip medical misinformation has has done more to frighten patients from a biologic that could improve their QOL.

You know nothing about the etiology of PML. You know nothing about the pharmacokinetics of Tysabri. You're mouthing inuendo and pseudoscience you've heard from others. That's sad, very, very sad!

Tysabri has never been implicated in PML when used as monotherapy. Remicade on the other hand, has!

Even as write what I had hoped would be a charitable critique I am steaming inside at the potential harm you might have caused with your careless disreguard for the facts.

Please consider either learning to CAREFULLY research your work or perhaps confining your literary efforts to underwater basket weaving tutorials!

I do hope that you learn to temper your zeal; diligently dividing TRUTH from opinion!

John

I do have a small position in ELN